Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.

@article{Wallace1982ComparativeTO,
  title={Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.},
  author={Richard J. Wallace and S L Niefield and S C Waters and Bradford Waters and Robert Awe and Karen Wiss and Ralston R Martin and Stephen B Greenberg},
  journal={Antimicrobial agents and chemotherapy},
  year={1982},
  volume={21 2},
  pages={231-5}
}
Cefonicid (Smith Kline & French Laboratories; D-75073) is a new parenteral cephalosporin with a markedly long half-life, high serum levels, and good in vitro activity against Haemophilus influenzae. Patients with community-acquired pneumonia were randomized 2:1 to receive cefonicid, 1 g daily (21 cases) or cefamandole, 1 g every 6 h (12 cases). The two groups were similar, except that the cefonicid patients were older (mean 42 versus 31 years). Peak serum levels of cefonicid averaged 133… CONTINUE READING